       Document 0231
 DOCN  M9440231
 TI    Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes
       during HIV-1 infection.
 DT    9404
 AU    Choremi-Papadopoulou H; Viglis V; Gargalianos P; Kordossis T;
       Iniotaki-Theodoraki A; Kosmidis J; Dept of Immunology, Laiko General
       Hospital, Athens, Greece.
 SO    J Acquir Immune Defic Syndr. 1994 Mar;7(3):245-53. Unique Identifier :
       AIDSLINE MED/94149558
 AB    A progressive significant decrease of CD28 surface antigen expression on
       CD4+ (mean, 90, 86, 79, 68% in stages I, II, III, and IV, respectively,
       versus 96% in normals), as well as on CD8+ T lymphocytes (mean, 38, 32,
       31, and 29% in stages I, II, III, and IV, respectively, versus 47% in
       normals) was observed during HIV-1 infection. The increase of
       cytotoxic/suppressor T cells, in both percentage and absolute numbers,
       that was observed in almost all HIV-1 patients, was associated with an
       increase of the CD8+ cells lacking the CD28 surface antigen. The loss of
       CD28 antigen expression was parallel to the increase of CD38, human
       leukocyte antigen (HLA)-DR, and CD45RO antigen expression on T
       lymphocytes throughout the disease. Furthermore, a positive significant
       correlation within the CD4+ but not the CD8+ subset was observed between
       the percentage of cells lacking the CD28 antigen and the percentage of
       cells expressing the HLA-DR and CD38 antigens, a finding suggesting that
       the loss of CD28 antigen expression on CD4+ lymphocytes may be
       associated with T-lymphocyte activation. Patients treated with
       zidovudine showed no significant differences in the percentages of
       either CD4+CD28+ or CD8+CD28+ T-cell subsets when compared to untreated
       patients. These phenotypic changes may be associated with the functional
       defects of T lymphocytes in HIV-1 infected individuals.
 DE    Adult  Antigens, CD28/*METABOLISM  *Down-Regulation (Physiology)  Female
       Flow Cytometry  Fluorescent Antibody Technique  Human  HIV
       Infections/DRUG THERAPY/*IMMUNOLOGY  HIV-1/*IMMUNOLOGY  Lymphocyte
       Transformation  Male  Middle Age  T-Lymphocyte Subsets/*IMMUNOLOGY
       T-Lymphocytes, Suppressor-Effector/IMMUNOLOGY  T4 Lymphocytes/IMMUNOLOGY
       Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

